Preferred Label : Ispectamab Debotansine;
NCIt synonyms : Anti-BCMA Antibody Drug Conjugate CC-99712; Anti-BCMA ADC CC-99712; Anti-BCMA Antibody-drug Conjugate CC-99712;
NCIt definition : An antibody-drug conjugate (ADC) consisting of ispectamab, a humanized immunoglobulin
G1 (IgG1)-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell
maturation antigen (BCMA; tumor necrosis factor (TNF) receptor superfamily, member
17; TNFRSF17) site-specifically conjugated, with a non-cleavable linker, to a maytansinoid
payload, with potential antineoplastic activity. Upon administration of ispectamab
debotansine, the ispectamab moiety targets and binds to the cell surface antigen BCMA
expressed on certain cancer cells. Upon binding and internalization, the maytansinoid
payload binds to tubulin, thereby affecting microtubule assembly/disassembly dynamic,
and prevents cell division and reduces cell growth of BCMA-expressing cancer cells.
BCMA, a receptor for a proliferation-inducing ligand (APRIL; TNF ligand superfamily
member 13; TNFSF13), and B-cell activating factor (BAFF), is overexpressed on malignant
plasma cells and plays a key role in plasma survival.;
UNII : WY39ZX6NZU;
CAS number : 2413386-21-5;
Molecule name : CC 99712; CC-99712; BMS-986352;
NCI Metathesaurus CUI : CL1383075;
Origin ID : C170915;
UMLS CUI : C5783386;
Semantic type(s)
- concept_is_in_subset
- has_target
